Promising News for Sinus Sufferers: New Treatment Option Shows Positive Results — and Richmond ENT Helped Prove It Works

If you struggle with chronic sinus infections, you know how frustrating and exhausting it can be. Constant congestion, facial pressure, and difficulty breathing can take a toll on your quality of life — especially when medications and repeated antibiotics just aren’t enough.

Now, there’s new hope.

Lyra Therapeutics recently announced exciting results from a national Phase 3 clinical trial of LYR-210, a new, non-surgical treatment for chronic rhinosinusitis (CRS). The device is a small, bioabsorbable implant placed in the nose that delivers anti-inflammatory medication directly to the sinus tissue over several months. This sustained delivery helps reduce swelling, improve breathing, and relieve sinus pressure — all without the need for daily sprays or pills.

Dr. Mike Armstrong of Richmond ENT was one of the principal investigators in this study, helping lead the national trial known as ENLIGHTEN 2. Richmond ENT was proud to be one of the research sites that helped demonstrate the safety and effectiveness of this breakthrough therapy.

The results? Patients using LYR-210 showed significant improvement in sinus symptoms compared to those who received a placebo — including relief from nasal blockage, facial pain, and congestion.

Pending FDA approval, this new treatment may soon offer relief for patients who want to avoid sinus surgery but haven’t gotten better with medications alone.

If you’ve been living with chronic sinus issues and want to explore new options, Richmond ENT is here to help. Call us at (804) 330-5501 or visit www.richmondent.com to schedule a consultation.